Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model

Transplantation

Volumn 87, Issue 2, 2009, Pages 178-188

  Hummel, Mary ^a   Kurian, Sunil M ^b   Lin, Simon ^a   Borodyanskiy, Aleksey ^a   Zhang, Zheng ^a   Li, Zhigao ^a   Kim, Soo Jung ^c   Salomon, Daniel R ^b   Abecassis, Michael ^a,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Rosalind Franklin Institute   (United States)

^d NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Allograft; Gene expression profiling; TNF

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ANTIGEN; CD40 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; H2 DMB ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 6; ONCOSTATIN M RECEPTOR; PSMB8 ANTIGEN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; CYTOKINE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; INNATE IMMUNITY; KIDNEY ALLOGRAFT; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ALLOTRANSPLANTATION; ANIMAL; ANIMAL MODEL; C3H MOUSE; C57BL MOUSE; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; METABOLISM; METHODOLOGY; MOUSE MUTANT; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; TIME;

ANIMALS; CYTOKINES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNITY, INNATE; INFLAMMATION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 59649108625     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181938971     Document Type: Article

References (76)

1. Gourishankar S, Halloran PF. Late deterioration of organ transplants: A problem in injury and homeostasis. Curr Opin Immunol 2002; 14: 576.
2. Christopher K, Mueller TF, Ma C, et al. Analysis of the innate and adaptive phases of allograft rejection by cluster analysis of transcriptional profiles. J Immunol 2002; 169: 522.
3. He H, Stone JR, Perkins DL. Analysis of robust innate immune response after transplantation in the absence of adaptive immunity. Transplantation 2002; 73: 853.
4. Kim J, Chang CK, Hayden T, et al. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection. J Immunol 2007; 179: 6416.
5. Mueller TF, Ma C, Lederer JA, et al. Differentiation of stress, metabolism, communication, and defense responses following transplantation. J Leukoc Biol 2003; 73: 379.
6. Wasowska BA, Lee CY, Halushka MK, et al. New concepts of comple-mentinallorecognition and graft rejection. Cell Immunol 2007; 248: 18.
7. Wyburn KR, Jose MD,WuH, et al. The role ofmacrophagesin allograft rejection. Transplantation 2005; 80: 1641.
8. Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066.
9. Pascher A, Klupp J. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: New applications for TNFalpha inhibitors? Biodrugs 2005; 19: 211.
10. Hoffmann MW, Wonigeit K, SteinhoffG,et al. Productionof cytokines (TNF-alpha, IL-1-beta) and endothelial cell activation in human liver allograft rejection. Transplantation 1993; 55: 329.
11. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation 1990; 50: 219.
12. Maury CP, Teppo AM. Raised serum levelsofcachectin/tumor necrosis factor alpha in renal allograft rejection. J Exp Med 1987; 166: 1132.
13. Tilg H, Vogel W, Aulitzky WE, et al. Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation. Transplantation 1990; 49: 1074.
14. Wiggins MC, Bracher M, Mall A, et al. Tumour necrosis factor levels during acute rejection and acute tubular necrosis in renal transplant recipients. Transpl Immunol 2000; 8: 211.
15. Kutukculer N, Shenton BK, Clark K, et al. Renal allograft rejection: The temporal relationship and predictive value of plasma TNF (alpha and beta), IFN-gamma and soluble ICAM-1. Transpl Int 1995; 8: 45.
16. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats. Transplantation 1990; 50: 189.
17. Machen J, Bertera S, Chang Y, et al. Prolongation of islet allograft survival following ex vivo transduction with adenovirus encoding a soluble type 1 TNF receptor-Ig fusion decoy. Gene Ther 2004; 11: 1506.
18. McKee CM, Defina R, He H, et al. Prolonged allograft survival in TNF receptor 1-deficient recipients is due to immunoregulatory effects, not to inhibition of direct antigraft cytotoxicity. J Immunol 2002; 168: 483.
19. Suzuki J, Cole SE, Batirel S, et al. Tumor necrosis factor receptor-1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transplant 2003; 3: 968.
20. Tagawa T, Kozower BD, Kanaan SA, et al. Gene transfer of tumor necrosis factor inhibitor improves the function of lung allografts. J Thorac Cardiovasc Surg 2004; 127: 1558.
21. Hummel M, Zhang Z, Yan S, et al. Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: A model for reactivation from latency. J Virol 2001; 75: 4814.
22. Banno T, GazelA, BlumenbergM. Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes. J Biol Chem 2005; 280: 18973.
23. Sass G, Shembade ND, Tiegs G. Tumour necrosis factor alpha (TNF)-TNF receptor 1-inducible cytoprotective proteins in the mouse liver: Relevance ofsuppressors ofcytokine signalling. Biochem J 2005; 385 (Pt 2): 537.
24. Tian B, Nowak DE, Jamaluddin M, et al. Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J Biol Chem 2005; 280: 17435.
25. Zer C, Sachs G, Shin JM. Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-alpha signaling. Physiol Genomics 2007; 31: 343.
26. Einecke G, Broderick G, Sis B, et al. Early loss of renal transcripts in kidney allografts: Relationship to the development of histologic lesions and alloimmune effector mechanisms. Am J Transplant 2007; 7: 1121.
27. Famulski KS, Broderick G, Einecke G, et al. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant 2007; 7: 2483.
28. Famulski KS, Einecke G, Reeve J, et al. Changes in the transcriptome in allograft rejection: IFN-gamma-induced transcripts in mouse kidney allografts. Am J Transplant 2006; 6: 1342.
29. Kim SJ, Varghese TK, Zhang Z,et al. Renal ischemia/reperfusion injury activates the enhancer domain of the human cytomegalovirus major immediate early promoter. Am J Transplant 2005; 5: 1606.
30. Zhang Z, Schlachta C, Duff J, et al. Improved techniques for kidney transplantation in mice. Microsurgery 1995; 16: 103.
31. Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185.
32. Churchill GA. Using ANOVA to analyze microarray data. Biotechniques 2004; 37: 173.
33. Sahai H, Ageel M. The analysis of variance: Fixed, random, and mixed models. Boston, Birkhauser 2000.
34. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
35. Dostert C, Tschopp J. DEteCTINg fungal pathogens [comment]. Nat Immunol 2007; 8: 17.
36. Iizuka K, Naidenko OV, Plougastel BF, et al. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol 2003; 4: 801.
37. Taylor PR, Reid DM, Heinsbroek SE, et al. Dectin-2 is predominantly myeloid restricted and exhibits unique activation-dependent expression on maturing inflammatory monocytes elicited in vivo. Eur J Immunol 2005; 35: 2163.
38. Lohoff M, Ferrick D, Mittrucker HW, et al. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 1997; 6: 681.
39. Ogasawara K, Hida S, Azimi N, et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 1998; 391: 700; erratum appears in Nature 1998; 392: 843.
40. White LC, Wright KL, Felix NJ, et al. Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8+ T cells in IRF-1 - / - mice. Immunity 1996; 5: 365.
41. Taniguchi T, Ogasawara K, Takaoka A, et al. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19: 623.
42. Erickson L, Crews G, Pan F, et al. Unique gene expression profiles of heart allograft rejection in the interferon regulatory factor-1-deficient mouse. Transpl Immunol 2004; 13: 169.
43. Fujita T, Reis LF, Watanabe N, et al. Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways. Proc Natl Acad Sci USA 1989; 86: 9936.
44. Liu J, Ma X. Interferon regulatory factor 8 regulates RANTES gene transcription in cooperation with interferon regulatory factor-1, NF-kappaB, and PU. 1. J Biol Chem 2006; 281: 19188.
45. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: An overview of signals, mechanisms and functions. J LeukocBiol 2004; 75: 163.
46. Naugler WE, Karin M. The wolf in sheep's clothing: The role of inter-leukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109.
47. Luster AD. Chemokines - Chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436.
48. Andrade CF, Waddell TK, Keshavjee S, et al. Innate immunity and organ transplantation: The potential role of toll-like receptors. Am J Transplant 2005; 5: 969.
49. Goldstein DR. Toll like receptors and acute allograft rejection. Transpl Immunol 2006; 17: 11.
50. Land WG. The role of postischemic reperfusion injury and other non-antigen-dependent inflammatory pathways in transplantation. Transplantation 2005; 79: 505.
51. Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response [see comment]. Nature 2007; 448: 501.
52. Quezada SA, Jarvinen LZ, Lind EF, et al. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22: 307.
53. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004; 16: 76.
54. Walter W, Scheuer C, Loos M, et al. H2-Mbeta 1 and H2-Mbeta 2 heterodimers equally promote clip removal in I-A(q) molecules from autoimmune-prone DBA/1 mice. J Biol Chem 2001; 276: 11086.
55. He KL, Ting AT. A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells. Mol Cell Biol 2002; 22:6034.
56. Li Z, Nabel GJ. A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription. Mol Cell Biol 1997; 17: 6184.
57. Croker BA, Krebs DL, Zhang JG, et al. SOCS3 negatively regulates IL-6 signaling in vivo [see comment]. Nat Immunol 2003; 4: 540.
58. Gilchrist M, Thorsson V, Li B, et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 2006; 441: 173.
59. Stross C, Radtke S, Clahsen T, et al. Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism. J Biol Chem 2006; 281: 8458.
60. Paludan SR. Synergistic action of pro-inflammatory agents: Cellular and molecular aspects. J Leukoc Biol 2000; 67: 18.
61. Collins T, Read MA, Neish AS, et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995; 9: 899.
62. Li J, Brieher WM, Scimone ML, et al. Caspase-11 regulates cell migration by promoting Aip1-Cofilin-mediated actin depolymerization [see comment]. Nat Cell Biol 2007; 9: 276;
63. erratum appears in Nat Cell Biol 2007; 9: 480.
64. Wang S, Miura M, Jung YK, et al. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell 1998; 92: 501.
65. Liu L, Cara DC, Kaur J, et al. LSP1 is an endothelial gatekeeper of leukocyte transendothelial migration. J Exp Med 2005; 201: 409.
66. Liu N, Wang Y, Ashton-Rickardt PG. Serine protease inhibitor 2A inhibits caspase-independent cell death. FEBS Lett 2004; 569: 49.
67. Remick DG, Green LB, Newcomb DE, et al. CXC chemokine redundancy ensures local neutrophil recruitment during acute inflammation. Am J Pathol 2001; 159: 1149.
68. Liang TS, Wang JM, Murphy PM, et al. Serum amyloid A is a chemotactic agonist at FPR2, a low-affinity N-formylpeptide receptor on mouse neutrophils. Biochem Biophys Res Commun 2000; 270: 331.
69. Vandal K, Rouleau P, Boivin A, et al. Blockade of S100A8 and S100A9 suppresses neutrophil migration in responseto lipopolysaccharide [see comment]. J Immunol 2003; 171: 2602.
70. Li Q, Park PW, Wilson CL, et al. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002; 111: 635.
71. ModurV,Feldhaus MJ, Weyrich AS,et al. Oncostatin M is aproinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 1997; 100: 158.
72. Hai T, Hartman MG. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: Activating transcription factor proteins and homeostasis. Gene 2001; 273: 1.
73. Droin NM, Pinkoski MJ, Dejardin E, et al. Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. Mol Cell Biol 2003; 23: 7638.
74. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772.
75. Goruppi S, Patten RD, Force T, et al. Helix-loop-helix protein p8, a transcriptional regulator required for cardiomyocyte hypertrophy and cardiac fibroblast matrix metalloprotease induction. Mol Cell Biol 2007; 27: 993.
76. Hipp MS, Kalveram B, Raasi S, et al. FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol 2005; 25: 3483.